Neuralight's Eye-Movement Software and the MDS-UPDRS
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Neuralight's Eye-Movement Software and the MDS-UPDRS
-
Narrated by:
-
By:
In this episode, we sit down with Dr. Eitan Raveh, VP of Clinical Partnerships at NeuraLight, to explore a technology that could reshape how Parkinson's disease is measured and tracked in clinical trials. For nearly four decades, the MDS-UPDRS has been the gold standard for evaluating Parkinson's progression, but a new study suggests that a simple eye-tracking test, administered on a tablet in about ten minutes, may be more sensitive at detecting disease progression than the scale neurologists have relied on for generations. Dr. Raveh walks us through NeuraLight's landmark longitudinal study, what the Amplitude of Saccadic Hypometria actually measures, and why two of the scientists who helped build the MDS-UPDRS are now co-authors on a paper showing it may have met its match. If you follow Parkinson's research, drug development, or the future of digital biomarkers in neurology, this is a conversation you won't want to miss.